Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 1/20 | 0.49 |
| ▸ | SELP | P16109 | 1/20 | 0.49 |
| ▸ | SELE | P16581 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471275 | 0.83 | RIPK1 (0.61) | KMT2AMMP8ALDH1A1MEN1HDAC6 | |
| SCHEMBL4765237 | 0.83 | RIPK1 (0.61) | KMT2AMMP8ALDH1A1MEN1HDAC6 | |
| SCHEMBL3196978 | 0.83 | MLYCD (0.54) | KMT2AALDH1A1SRD5A2MEN1HDAC6 | |
| SCHEMBL15372391 | 0.83 | EPHX2 (0.48) | KMT2ANR1H4EPHX2ALDH1A1HDAC6 | |
| SCHEMBL12188585 | 0.82 | HDAC6 (0.71) | KMT2ANR1H4EPHX2MMP8ALDH1A1 | |
| SCHEMBL506307 | 0.81 | MTOR (0.54) | NR1H4EPHX2ALDH1A1HDAC6 | |
| SCHEMBL2054822 | 0.81 | EPHX2 (0.50) | KMT2ANR1H4EPHX2ALDH1A1MEN1 | |
| SCHEMBL8072288 | 0.81 | LOXL2 (0.53) | KMT2ANR1H4EPHX2ALDH1A1MEN1 | |
| SCHEMBL25295609 | 0.80 | NR1H4 (0.58) | KMT2ANR1H4ALDH1A1 | |
| SCHEMBL15013037 | 0.80 | SMN1; SMN2 (0.56) | KMT2ANR1H4EPHX2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462760-A | Fluorescence-labeled ddNTP, synthesis method and application thereof, DNA sequencing kit and preparation method thereof | 河北迪纳兴科生物科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| EP-4631931-A1 | HDAC INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025041160-A1 | BIFUNCTIONAL CONJUGATE MOLECULES FOR CANCER TREATMENT AND PROCESS OF MAKING THE SAME | BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE (BITS), PILANI (IN) | 2025-02-27 | — | — | WO | disclosed |
| CN-119462760-A | Fluorescence-labeled ddNTP, synthesis method and application thereof, DNA sequencing kit and preparation method thereof | 河北迪纳兴科生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | OCEAN UNIVERSITY OF CHINA (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20230160001-A1 | NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-05-25 | — | — | US | disclosed |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| CN-115703736-A | Multi-target inhibitors targeting HDAC and NAD synthesis and uses thereof | 中国海洋大学 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023011416-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | 中国海洋大学 | 2023-02-09 | — | — | WO | disclosed |
| US-11400130-B2 | Inhibitors for proliferating cell nuclear antigen and uses | PURDUE RESEARCH FOUNDATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| EP-0923597-B1 | SUBSTITUTED PROPARGYLETHOXYAMIDO NUCLEOSIDES | PE CORP NY (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0923597-A1 | SUBSTITUTED PROPARGYLETHOXYAMIDO NUCLEOSIDES | THE PERKIN-ELMER CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998045310-A1 | SUBSTITUTED PROPARGYLETHOXYAMIDO NUCLEOSIDES | THE PERKIN-ELMER CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5770716-A | CHAIN TERMINATING AND CHAIN EXTENDING NUCLEOTIDES, PRIMER EXTENSION REACTIONS, DNA SEQUENCING, POLYMERASE CHAIN REACTION | THE PERKIN-ELMER CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | KMT2A 794/4885NR1H4 3610/4885EPHX2 3971/4885 |
| US-11400130-B2 | Inhibitors for proliferating cell nuclear antigen and uses | MKI67, PCNA, PCLAF | KMT2A 1025/4885NR1H4 1406/4885EPHX2 3869/4885 |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | HDAC3, HDAC1, HDAC11 | KMT2A 138/4885NR1H4 200/4885EPHX2 990/4885 |
| US-20230137943-A1 | PHOTOPROXIMITY PROFILING OF PROTEIN-PROTEIN INTERACTIONS IN CELLS | PPIA, S100A4, S100A6 | KMT2A 3560/4885NR1H4 4505/4885EPHX2 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.